Cargando…

Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis

BACKGROUND: The addition of cetuximab significantly increased the antitumor effect of programmed cell death protein 1 (PD-1) inhibitors in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, preliminary analyses suggested that human papillomavirus (HPV)-positive disease b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Siqi, Zheng, Mengge, Nie, Deheng, Xu, Lili, Tian, Huimin, Wang, Mengmeng, Liu, Wenjia, Feng, Zhenbang, Han, Fujun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577924/ https://www.ncbi.nlm.nih.gov/pubmed/36253001 http://dx.doi.org/10.1136/jitc-2022-005158

Ejemplares similares

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
por: Ferris, Robert L, et al.
Publicado: (2021)

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
por: Zandberg, Dan P, et al.
Publicado: (2021)

Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
por: Lonardi, Sara, et al.
Publicado: (2021)

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
por: Leighl, Natasha B, et al.
Publicado: (2021)

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021)

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
por: Vavolizza, Rick D, et al.
Publicado: (2022)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
por: Cho, Byoung Chul, et al.
Publicado: (2020)

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
por: Clingan, Philip, et al.
Publicado: (2023)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2021)

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
por: Johnson, Jennifer M, et al.
Publicado: (2023)

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
por: Zhang, Wenwen, et al.
Publicado: (2023)

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition
por: Crist, McKenzie, et al.
Publicado: (2022)

PD1 blockade enhances K(+) channel activity, Ca(2+) signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer
por: Newton, Hannah S, et al.
Publicado: (2020)

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
por: Smalley Rumfield, Claire, et al.
Publicado: (2020)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
por: Seto, Takashi, et al.
Publicado: (2022)

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
por: Zucali, Paolo Andrea, et al.
Publicado: (2022)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
por: Zhong, Hua, et al.
Publicado: (2023)

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
por: Leidner, Rom, et al.
Publicado: (2021)

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
por: Guigay, Joël, et al.
Publicado: (2021)

PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression
por: Zhang, Zhiwei, et al.
Publicado: (2023)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
por: Kurino, Taiki, et al.
Publicado: (2020)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2021)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
por: Tsai, Yo-Ting, et al.
Publicado: (2022)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2020)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
por: Speetjens, Frank M, et al.
Publicado: (2022)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
por: Homicsko, Krisztian, et al.
Publicado: (2023)

ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response
por: de Sousa, Luana Guimaraes, et al.
Publicado: (2022)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
por: Kowalczyk, Joshua T, et al.
Publicado: (2022)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sv3iij31ed98m4flk6p7qgfl6v